An interventional study of standard of care in Sickle Cell Disease (SCD) and Vaso-occlusive Events, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment
Among 12 studies in Vaso-Occlusive Crises by Assistance Publique - Hôpitaux de Paris — 5 open to participants now, 5 under way, 1 of them phase 3. Vaso-Occlusive Crises · Assistance Publique - Hôpitaux de Paris.
Among the 12 studies in Vaso-Occlusive Crises by Assistance Publique - Hôpitaux de Paris, this one is the 7th largest by planned enrollment of the 11 interventional ones, is one of 4 that started in 2026, is one of 7 with no phase, and was the 11th registered.
104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.
This study's planned enrollment of 30 is below the median of 81 across 86 interventional studies indexed under Vaso-Occlusive Crises.
Browse Vaso-Occlusive Crises studies →5 of the 12 studies in Vaso-Occlusive Crises by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Each count lists the studies.
Of the 17 Vaso-Occlusive Crises studies recruiting now, 7 (41%) set no upper age limit and 6 (35%) stop at 75 or younger; 10 take children under 18; 1 take healthy volunteers.
This study: 12 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →12 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2026.
Median enrollment 40 across the 11 interventional studies, 200 across the 1 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Vaso-Occlusive Crises by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
The purpose of this study is to compare the efficacy and safety of transplantation of gene modified autologous CD34+ cells in SCD patients within a therapeutic strategy that may include anti-inflammatory treatment as a pre-transplant treatment in case of severe inflammation detected at the inclusion analysis; the autologous CD34+ cell will be transduced by the bifunctional βAS3m/miR7m lentiviral vector expressing the therapeutical beta-globin, βAS3m, and the miRNA anti-HbS vs Standard Of Care (SOC).
Sickle cell disease is a severe hemoglobinopathy characterized by anemia, chronic hemolysis, and vaso-occlusive crises, leading to high morbidity and mortality.
Medical management options or Standard Of Care (SOC) currently available for SCD include supportive management of VOC, long-term RBC transfusions, and foetal haemoglobin (HbF) induction with hydroxyurea (HU).
Hematopoietic stem cell transplantation is curative but available only for a minority of patients. Gene therapy approaches (gene addition or gene editing) have shown significant reductions in vaso-occlusive events, but residual hemolysis persists and their truly curative potential remains uncertain.
In France, the absence of a control arm in clinical trials has limited regulatory approval, supporting the development of the DREPAMIR protocol, which incorporates a Standard Of Care control group to better assess the efficacy clinical value and cost effectiveness of gene therapy in severe sickle cell disease.
The aim of this study is to compare the efficacy and safety of transplantation of gene modified autologous CD34+ cells in SCD patients within a therapeutic strategy that may include anti-inflammatory treatment as a pre-transplant treatment in case of severe inflammation detected at the inclusion analysis; the autologous CD34+ cell will be transduced by the bifunctional βAS3m/miR7m lentiviral vector expressing the therapeutical beta-globin, βAS3m, and the miRNA anti-HbS vs Standard Of Care (SOC).
Drepamir-SOC is the control arm of the main study DREPAMIR (NCT07432867)
104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.
This study's planned enrollment of 30 is below the median of 81 across 86 interventional studies indexed under Vaso-Occlusive Crises.
Browse Vaso-Occlusive Crises studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.
Compared within Vaso-Occlusive Crises, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anemia, Sickle Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least 3 vaso-occlusive crises requiring hospitalization, under hydroxyurea or transfusion, within 2 years prior to enrollment One severe acute chest syndrome (ACS) hospitalized in the intensive care unit At least 2 episodes of ACS, including one under HU. Acute priapism (at least 2 episodes >3h in the preceding year or in the year prior to the start of a regular transfusion program), OR stuttering priapism ≥ 1 by week under sickle cell treatment (HU, transfusion or phlebotomy).
Tricuspid regurgitation velocity >2.8m/s on cardiac echocardiograph without pulmonary hypertension confirmed by right heart catheterization (mPAP>\<25mmHg)
Exclusion Criteria :
Evaluations within 6 months prior to screening visit:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard of care
Drug: standard of care
Supportive management of VOC, long-term RBC transfusions, and foetal haemoglobin (HbF) induction with hydroxyurea (HU) Myocardic MRI (evaluation of function and fibrosis) + hematocrit measurement QoL questionnaires Imaging (brain MRI, transcranial and cervical ultrasound) Cardiac US, ECG Cardiac and Liver MRI (Fe assessment) Physical ability assessments Neuropsychological assessments Fertility
Disease-related mortality
Time frame: Up to the 24 months follow-up
All-cause mortality
Time frame: Up to the 24 months follow-up
Occurrence of vaso-occlusive events
Time frame: between 3 and 15 months following IV infusion of DREAM01 of the corresponding matched DREPAMIR patient
Percentage of HbS
Measure of HbS
Time frame: Up to the 24 months follow-up
Percentage of HbF
Measure of HbF
Time frame: Up to the 24 months follow-up
Rate of Hemolysis
Biological parameters that reflect hemolysis : Total hemoglobin, Reticulocytes, lactate dehydrogenase LDH, circulating erythroblasts, haptoglobin, free plasmatic heme, no conjugated bilirubin, erythropoietin EPO
Time frame: Up to the 24 months follow-up
Rate of Anemia
Biological parameters that reflect anemia : Total hemoglobin, Reticulocytes, lactate dehydrogenase LDH, circulating erythroblasts, haptoglobin, free plasmatic heme, no conjugated bilirubin, erythropoietin EPO
Time frame: Up to the 24 months follow-up
Transfusion requirement
absence of vaso-occlusive events (VOE) in patients who have discontinued the transfusion program or/and hydroxyurea
Time frame: Up to the 24 months follow-up
Change in number of units of RBCs transfused
Time frame: Up to the 24 months follow-up
Changes in brain function
Occurrence of ischemic lesions, vascular stenosis, aneurysm assessed using cervical doppler ultrasound and cerebral MRI
Time frame: Up to the 24 months follow-up
Changes in brain function
Occurrence of pathological flow acceleration or vascular stenosis using carotid and transcranial Doppler ultrasound
Time frame: Up to the 24 months follow-up
Changes in ocular function
Assessed Using Fundus examination
Time frame: Up to the 24 months follow-up
Changes in ocular function
Assessed Using angiography
Time frame: Up to the 24 months follow-up
Changes in cardiac function
Evaluated through electrocardiographic (ECG) assessment : overall interpretation with 3 categories such as Normal/ Abnormal, not clinically significant/ Abnormal, clinically significant
Time frame: Up to the 24 months follow-up
Changes in the occurrence of left ventricular ejection fraction [LVEF] right and left atrial
Occurrence of left ventricular ejection fraction \[LVEF\], right and left atrial, left assessed using cardiac ultrasound.
Time frame: Up to the 24 months follow-up
Changes in the occurrence of left ventricular ejection fraction [LVEF] right and left atrial
Occurrence of left ventricular ejection fraction \[LVEF\], right and left atrial, left assessed using cardiac MRI (including myocardial imaging)
Time frame: Up to the 24 months follow-up
Changes in the occurrence of left ventricular ejection fraction [LVEF] right and left atrial
Occurrence of left ventricular ejection fraction \[LVEF\], right and left atrial, left assessed using Doppler echocardiography.
Time frame: Up to the 24 months follow-up
Changes in the occurrence of left ventricular ejection fraction [LVEF] right and left atrial
Occurrence of left ventricular ejection fraction \[LVEF\], right and left atrial, left assessed using transthoracic echocardiography
Time frame: Up to the 24 months follow-up
Changes in left ventricular size
Changes in left ventricular size assessed using cardiac ultrasound.
Time frame: Up to the 24 months follow-up
Changes in left ventricular size
Changes in left ventricular size assessed using cardiac MRI (including myocardial imaging)
Time frame: Up to the 24 months follow-up
Changes in left ventricular size
Changes in left ventricular size assessed using Doppler echocardiography
Time frame: Up to the 24 months follow-up
Changes in left ventricular size
Changes in left ventricular size assessed using transthoracic echocardiography
Time frame: Up to the 24 months follow-up
Changes in left ventricular wall thickness
Changes in the left ventricular wall thickness assessed using cardiac ultrasound.
Time frame: Up to the 24 months follow-up
Changes in left ventricular wall thickness
Changes in the left ventricular wall thickness assessed using cardiac MRI (including myocardial imaging)
Time frame: Up to the 24 months follow-up
Changes in left ventricular wall thickness
Changes in the left ventricular wall thickness assessed using Doppler echocardiography
Time frame: Up to the 24 months follow-up
Changes in left ventricular wall thickness
Changes in the left ventricular wall thickness assessed using transthoracic echocardiography
Time frame: Up to the 24 months follow-up
Changes in systolic pulmonary artery pressure [sPAP ]
Changes in systolic pulmonary artery pressure \[sPAP\], assessed using cardiac ultrasound.
Time frame: Up to the 24 months follow-up
Changes in systolic pulmonary artery pressure [sPAP ]
Changes in systolic pulmonary artery pressure \[sPAP\], assessed using cardiac MRI (including myocardial imaging)
Time frame: Up to the 24 months follow-up
Changes in systolic pulmonary artery pressure [sPAP ]
Changes in systolic pulmonary artery pressure \[sPAP\], assessed using Doppler echocardiography
Time frame: Up to the 24 months follow-up
Changes in systolic pulmonary artery pressure [sPAP ]
Changes in systolic pulmonary artery pressure \[sPAP\], assessed using transthoracic echocardiography
Time frame: Up to the 24 months follow-up
Changes in tricuspid regurgitation velocity [TRV ]
Changes in tricuspid regurgitation velocity \[TRV\] assessed using cardiac ultrasound
Time frame: Up to the 24 months follow-up
Changes in tricuspid regurgitation velocity [TRV ]
Changes in tricuspid regurgitation velocity \[TRV\] assessed using cardiac MRI (including myocardial imaging)
Time frame: Up to the 24 months follow-up
Title : Changes in tricuspid regurgitation velocity [TRV]
Changes in tricuspid regurgitation velocity \[TRV\] assessed using Doppler echocardiography
Time frame: Up to the 24 months follow-up
Title : Changes in tricuspid regurgitation velocity [TRV]
Changes in tricuspid regurgitation velocity \[TRV\] assessed using transthoracic echocardiography
Time frame: Up to the 24 months follow-up
Changes in E/A ratio
Changes in of E/A ratio assessed using cardiac ultrasound, cardiac MRI (including myocardial imaging), Doppler echocardiography and transthoracic echocardiography
Time frame: Up to the 24 months follow-up
Change in serum electrolyte panel
Time frame: Up to the 24 months follow-up
Change in serum creatinine
Time frame: Up to the 24 months follow-up
Change in estimated glomerular filtration rate (eGFR )
Renal function assessed through estimated glomerular filtration rate (eGFR) calculated using CKD-EPI equation
Time frame: Up to the 24 months follow-up
Change in urinary microalbumin
Time frame: Up to the 24 months follow-up
Change in protein excretion
Time frame: Up to the 24 months follow-up
Change in urinary creatinine
Time frame: Up to the 24 months follow-up
Changes in creatinine clearence
Time frame: Up to the 24 months follow-up
Change in liver enzyme AST
Time frame: Up to the 24 months follow-up
Change in liver enzyme ALT
Time frame: Up to the 24 months follow-up
Change in liver enzyme GGT
Time frame: Up to the 24 months follow-up
Changes in in liver enzyme ALP
Time frame: Up to the 24 months follow-up
Change in total bilirubin
Time frame: Up to the 24 months follow-up
Change in unconjugated (free) bilirubin
Time frame: Up to the 24 months follow-up
Changes in hepatic function
overall interpretation with 3 categories such as Normal/ Abnormal, not clinically significant/ Abnormal, clinically significant
Time frame: Up to the 24 months follow-up
Change in diffusing capacity for carbon monoxide (DLCO )
Time frame: Up to the 24 months follow-up
Change in vital capacity (VC )
Time frame: Up to the 24 months follow-up
Change in residual volume (RV )
Time frame: Up to the 24 months follow-up
Change in FEV1/FVC ratio (Tiffeneau index )
Time frame: Up to the 24 months follow-up
Changes in bone metabolism
Assessed through osteodensitometry
Time frame: Up to the 24 months follow-up
Changes in muscular function
Overall interpretation with 3 categories such as Normal/ Abnormal, not clinically significant/ Abnormal, clinically significant
Time frame: Up to the 24 months follow-up
Occurrence of iron overload
Time frame: Up to the 24 months follow-up
Fertility evaluation
Assessed through hormonal testing
Time frame: Up to the 24 months follow-up
Quality of life Evaluation: patient health
Medical Outcomes Study Short Form 36 SF-36 The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. 0-100 scale so that a higher score indicates a better outcome.
Time frame: Up to the 24 months follow-up
Quality of life Evaluation : fatigue
FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue Scale) FACIT-Fatigue is a 13-item self-report scale that assesses fatigue and its effect on daily activities and function. 0-52 scale so that a higher score indicates a better outcome.
Time frame: Up to the 24 months follow-up
Quality of life Evaluation: physical , mental, and social health
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. PROMIS domain scores are reported as T-scores, with a mean of 50 and a standard deviation of 10 in the reference population. Higher scores indicate better health for physical function and ability to participate in social roles and activities, whereas higher scores indicate worse health for fatigue, pain interference, depressive symptoms, anxiety, and sleep disturbance.
Time frame: Up to the 24 months follow-up
Health-realted Quality of life Evaluation
Pediatric Quality of Life Inventory (PedsQL ) Generic Core Scales PedsQL is a modular system that assesses health-related quality of life in healthy and ill children and adolescents. It combines generic core scales and disease-specific modules into one measurement system. 0-100 scale, so that higher scores indicate better outcome.
Time frame: Up to the 24 months follow-up
Walk ability
6-minute walk-test
Time frame: Up to the 24 months follow-up
jump
Vertical jump test : The jump height will be recorded using video analysis software. The average height of the 3 jumps will be calculated
Time frame: Up to the 24 months follow-up
Physical ability
physical ability questionnaire, using the Global physical activity questionnaire (GPAQ) (16 items) developed by WHO. Minimum value is 0 with no theoretical maximum value. Higher scores indicate better outcome.
Time frame: Up to the 24 months follow-up
Cardiopulmonary capacity
Cardiopulmonary exercise test, using the Cardio Pulmonary Exercise Test
Time frame: Up to the 24 months follow-up
Costs
Costs of treatment calculated yearly and cost per event (VOC and ATS)
Time frame: Up to the 24 months follow-up
Cost effectiveness
Model-based incremental cost effectiveness ratio of gene therapy with inputs for SoC
Time frame: Up to the 24 months follow-up
Changes in cardiac global function
Assessed through cardiac magnetic resonance imaging, using ventricular function - Overall interpretation with 3 categories such as Normal/ Abnormal, not clinically significant/ Abnormal, clinically significant
Time frame: Up to the 24 months follow-up
Changes in myocardial tissular
Using late gadolinium myocardial enhancement
Time frame: Up to the 24 months follow-up
Changes in myocardial tissular
Using native T1 mapping
Time frame: Up to the 24 months follow-up
Changes in myocardial tissular
Using extracellular volume
Time frame: Up to the 24 months follow-up
Changes in myocardial tissular
Using diffusion tensor imaging (DTI)
Time frame: Up to the 24 months follow-up
Start is estimated for Sep 2026; primary completion for Mar 2030, 42 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →